CUPR
Cuprina Holdings (Cayman) Ltd
$
7.790
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
7.800
Open
7.750
VWAP
7.72
Vol
274.63K
Mkt Cap
167.10M
Low
7.700
Amount
2.12M
EV/EBITDA(TTM)
--
Total Shares
21.45M
EV
166.31M
EV/OCF(TTM)
--
P/S(TTM)
--
Cuprina Holdings (Cayman) Limited is a biomedical and biotechnology company, which is engaged in the development and commercialization of products for the management of chronic wounds, as well as operating in the health and beauty sector. Its segments include Maggot Debridement Therapy Product (MDT) and Cosmeceutical Product. It manufactures and distributes a line of medical grade sterile blowfly larvae bio-dressing products marketed under the MEDIFLY brand name, or the MEDIFLY products. The MEDIFLY products are used as a biological debridement tool for chronic wounds, in a procedure known as MDT, which is an effective alternative to surgical debridement. It has two lines of chronic wound care products in its pipeline, such as Collagen dressings, including sponges, particles and hydrogels utilizing bullfrog collagen derived from the valorization of abattoir waste streams of American bullfrogs (Lithobates catesbeianus) and products utilizing medical leeches for wound treatment.
Show More
Valuation Metrics
The current forward P/E ratio for Cuprina Holdings (Cayman) Ltd (CUPR.O) is 0.00, compared to its 5-year average forward P/E of 0.00. For a more detailed relative valuation and DCF analysis to assess Cuprina Holdings (Cayman) Ltd 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
0.00
Current PE
0.00
Overvalued PE
0.00
Undervalued PE
0.00
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financials
Annual
Quarterly
FY2024Q4
-6.26
Gross Profit Margin - %
FY2024Q4
-3.23K
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
CUPR News & Events
Events Timeline
2025-07-21 (ET)
2025-07-21
09:06:21
Cuprina Holdings appoints Sherman as Medical, Scientific Director
2025-06-30 (ET)
2025-06-30
08:10:11
Cuprina provides update on research studies on three education institutes
2025-06-04 (ET)
2025-06-04
08:07:25
Cuprina MENA completed set-up of laboratory in Saudi Arabia
Sign Up For More Events
Sign Up For More Events
News
4.5
06-04NASDAQ.COMCuprina Expands Chronic Wound Care And Enters Medicinal Leech Market In MENA And GCC Regions
7.5
06-04NewsfilterCuprina Completes Lab Able to Supply MEDIFLY Chronic Wound Therapy Across MENA Region, Secures Exclusive License to Market Medicinal Leeches in GCC Countries
8.5
05-08NewsfilterCuprina Holdings Announces Closing of Underwriter's Over-Allotment Option in Connection with Initial Public Offering
Sign Up For More News
People Also Watch
META
Meta Platforms Inc
712.680
USD
-0.30%
MSFT
Microsoft Corp
513.710
USD
+0.55%
ORCL
Oracle Corp
245.120
USD
+0.94%
NVDA
NVIDIA Corp
173.500
USD
-0.14%
XOM
Exxon Mobil Corp
110.400
USD
-0.35%
AMZN
Amazon.com Inc
231.440
USD
-0.34%
AAPL
Apple Inc
213.880
USD
+0.06%
TSLA
Tesla Inc
316.060
USD
+3.52%
WMT
Walmart Inc
97.470
USD
+0.90%
AVGO
Broadcom Inc
290.180
USD
+0.51%
FAQ
What is Cuprina Holdings (Cayman) Ltd (CUPR) stock price today?
The current price of CUPR is 7.79 USD — it has increased 0.78 % in the last trading day.
What is Cuprina Holdings (Cayman) Ltd (CUPR)'s business?
What is the price predicton of CUPR Stock?
What is Cuprina Holdings (Cayman) Ltd (CUPR)'s revenue for the last quarter?
What is Cuprina Holdings (Cayman) Ltd (CUPR)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Cuprina Holdings (Cayman) Ltd (CUPR)'s fundamentals?
How many employees does Cuprina Holdings (Cayman) Ltd (CUPR). have?